BBC3 (BCL2 Binding Component 3)

While the observation of EDEM induction in the absence of statistically significant CHOP upregulation represents a low-power preliminary finding, the combined data support a cellular phenotype characterized by oxidative stress, caspase activation, and ER-associated transcriptional changes. Given its broad glycan recognition and lack of tumor selectivity, DmegA is not directly suitable for therapeutic applications, but the structural and mechanistic insights provided here inform future engineering or targeting strategies aimed at improving lectin selectivity.

These findings demonstrate that geniposide enhances cisplatin sensitivity in NSCLC by activating the p53-PUMA-mediated mitochondrial apoptotic pathway, thereby providing a potential strategy for overcoming chemotherapy resistance with improved safety.

At the molecular level, we revealed reduced pro-apoptotic ASPP1 and PUMA expression, elevated p21 and stabilized anti-apoptotic MCL1 and BCL-XL proteins in human HSPCs treated with cAMP pathway agonists. Overall, our findings highlight the pivotal role of PGE2/cAMP/CREB signaling axis as a central mediator of MSC-mediated protection of human HSPCs under genotoxic stress and identify pharmacological cAMP activation as a promising strategy to protect human HSPCs against DNA damage-induced hematotoxicity.

This study highlights PUMA as a potential prognostic indicator for CRC. Tau levels may also hold diagnostic value and could contribute to the development of non-invasive screening methods for early CRC detection, particularly within the Egyptian population, which remains underrepresented in current research.

Our data revealed the DXO-induced immediate transcriptomic response after 24 h, leading to germ cell death observed by histology at 48 h. These findings suggest that SSCs respond to DXO by favoring apoptosis and stress regulation, a strategy that may preserve germline integrity and reduce the risk of transmitting genetic damage to the next generation.

Indeed, this PARPi appeared to interact with immune checkpoints, stress sensors, and interfere with cell proliferation, leading to various types of cell death. As canine lymphoma is a significant concern in veterinary oncology and a valuable model for its human counterpart, this study further confirms the potential of PARPi as a therapeutic approach in hematological malignancies in both species.

Immune cell metabolic dysfunction is present in patients with uncomplicated infection before the clinical onset of sepsis. Early mitochondrial dysfunction and oxidative stress may represent promising targets for further investigation as early biomarkers of immune dysfunction and sepsis risk.

Accordingly, various viruses have evolved strategies to modulate host cell viability to their advantage by targeting PUMA-either by suppressing transcription of the PUMA gene, binding and inactivating the PUMA protein, or, conversely, inducing its production. In this work, we describe the role of PUMA in infections caused by distinct viruses and in associated diseases, viral strategies for modulating PUMA-related signaling pathways, and potential therapeutic implications.

In summary, paclitaxel induces transcriptomic and proteomic signatures of the neuronal stress response, neuroinflammation, nociception, and disturbed metabolism. These may explain, in part, the clinical phenotype of sensory loss, hypersensitivity, and neuropathic pain frequently observed in patients suffering from CIPN, but constitute pharmacologically addressable targets.

High expression of PUMA combined with low expression of p53 and a high expression of Ki-67 were independent unfavorable prognostic indicators for both OS and CSS. Further studies are required to clarify the prognostic and therapeutic role of these markers in CRC.

The in vivo efficacy was further supported by Ki-67 expression in tumor tissues. Taken together, our findings demonstrated that although the combination of Act D and resveratrol showed better efficacy in vitro than any of the single agent, the in vivo efficacy was not improved.

Preferred treatment options for advanced or recurrent EC patients include a combination of carboplatin and paclitaxel, with modest clinical outcomes...This study identified the novel small-molecule inhibitor AC1Q3QWB (AQB) as a potent enhancer of carboplatin efficacy...In vivo studies using subcutaneous xenografts and a stage IV EC patient-derived xenograft (PDX) model demonstrated that AQB enhanced carboplatin's antitumor effects, reduced the required carboplatin dose, and alleviated associated toxicity. The combination of AQB with standard chemotherapy holds promise for improving outcomes in patients with advanced or recurrent EC.The schematic diagram illustrates the mechanism by which AQB enhances the sensitivity of EC cells to CBPt.